Compare IDEXX Laboratories, Inc. (IDXX) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Exxon Mobil Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Exxon Mobil Corporation trades at $168.94 (market cap $692.86B). The key difference: Exxon Mobil Corporation is far larger — about 17.1× IDEXX Laboratories, Inc.'s market cap, and Exxon Mobil Corporation pays a 2.45% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Exxon Mobil Corporation for 99 Days on average.
| IDXX | XOM | |
|---|---|---|
Market Cap | $40.43B | $692.86B |
Volume | 692,164 | 13,225,996 |
Sector | Health | Energy |
52-Week High | $766.68 | $171.52 |
52-Week Low | $504.70 | $110.64 |
Typical Hold Time | 46 Days | 99 Days |
Enterprise Value | $41.32B | $724.64B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Exxon Mobil (XOM) trades at $168.56, up 2.74% today, with a bullish technical signal from moving averages and a consensus analyst price target of $166.67. Recent earnings show mixed results, with a Q2 2026 miss but beats in prior quarters. Revenue has declined from $398.7B in 2022 to $323.9B in 2025, though 2026 projects a rebound to $361.1B. News highlights potential investment in Venezuela's oil fields and expansion in Guyana and the Permian Basin.
XOM presents a stable investment with a 12.55% ROE and dividend yield, but faces risks from volatile oil prices and geopolitical ventures. Analyst sentiment is mixed with 36.36% buy ratings, indicating cautious optimism amid execution risks and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
